Tumor mutational burden (TMB) is a genomic biomarker with the potential to make a significant impact on the landscape of cancer immunotherapy. This emerging marker measures the number of mutations within a tumor genome and has already been shown to be associated with improved responses to checkpoint inhibitors.

It is defined as the number of non-inherited mutations per million bases of investigated genomic sequence, and its measurement has been enabled by next generation sequencing.